Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer: a Phase II Trial (PFROST)

NCT03439215 is registered in ClinicalTrials.gov with Fondazione Ricerca Traslazionale as lead sponsor.

NCT NCT03439215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03439215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer: a Phase II Trial (PFROST)
Lead sponsor
Fondazione Ricerca Traslazionale
Phase
Phase 2
Overall status
Unknown status
Start date
June 13, 2017
Completion date
June 30, 2022
Enrollment
20 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung